🚀 Apply for £10k+ grants with our Startup Launch Kit
shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD)?(U01 Clinical Trial Optional)

    PAR-23-258

    National Institutes of Health

    Opening date 16 Aug 2023, 12:00AM

    Closing date 5 Mar 2026, 12:00AM

    Funding Opportunity Number: PAR-23-258

    Opportunity Category: Discretionary

    CFDA Number(s): 93.866 -- Aging Research

    Cost Sharing or Matching Requirement: No

    Posted Date: Aug 16, 2023 12:00:00 AM EDT

    Closing Date: Mar 05, 2026 12:00:00 AM EST

    Award Ceiling: none

    Award Floor: none

    Eligible Applicants: State governments,Native American tribal governments (Federally recognized),Others (see text field entitled "Additional Information on Eligibility" for clarification),City or township governments,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Special district governments,County governments,Public and State controlled institutions of higher education,Small businesses,For profit organizations other than small businesses,Native American tribal organizations (other than Federally recognized tribal governments),Independent school districts,Public housing authorities/Indian housing authorities,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Private institutions of higher education

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

    Agency Name: National Institutes of Health

    Description: The goal of this Notice of Funding Opportunity (NOFO) is to accelerate the establishment ofeffective and reliable biomarkers of Alzheimers disease (AD) and AD-related dementias (ADRD) for usein therapy/medical product discovery and development, clinical trials and/or clinical practice. Specifically, this NOFO willsupport analytical and/or clinical validationof a biomarker, composite biomarker or biomarker signature, withrigor comparable with the expectations described in the Food and Drug Administration (FDA)Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways.

    Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept